TC Biopharm (Holdings) Plc (TCBPW) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Motherwell, United Kingdom. The current CEO is Bryan Leland Kobel.
TCBPW has 41 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $1.28K.
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
